Particle.news
Download on the App Store

Delani Diekmeier’s Scans Hold Stable as Next IMAZA Round Set for Feb. 11

The scan result suggests the targeted IMAZA therapy is holding the disease in check following months of setbacks.

Overview

  • An assessment at University Hospital Frankfurt found no new metastases and no growth of existing ones, which the family called a partial success.
  • In two to three weeks, Delani is scheduled to return to University Hospital Würzburg for another radioisotope treatment, with the visit set for February 11.
  • The oral component of the plan includes belzutifan, which the family says costs €17,830 per month on a private prescription with only partial reimbursement.
  • After the four-week tablet cycle, immunotherapy infusions are planned in Frankfurt every three weeks for a few months until the next CT scan.
  • Delani, 15, was diagnosed in early 2025 with an adrenal-region tumor that spread to her lungs after prior chemotherapies failed, and the family has continued treatment and fundraising after a palliative recommendation in Heidelberg, with €119,685 reported raised by January 27.